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ABSTRACT 
The aim of this study was to evaluate skin delivery of ketoprofen when covalently 
tethered to mildly cationic (2
+
 or 4
+
) peptide dendrimers prepared wholly by solid phase peptide 
synthesis. The amino acids glycine, arginine and lysine formed the dendrimer with ketoprofen 
tethered either to the lysine side-arm (Nε) or periphery of dendrimeric branches. Passive 
diffusion, sonophoresis- and iontophoresis-assisted permeation of each peptide dendrimer-drug 
conjugate (D1-D4) was studied across mouse skin, both in vitro and in vivo. In addition, skin 
toxicity of dendrimeric conjugates when trialed with iontophoresis or sonophoresis was also 
evaluated. All dendrimeric conjugates improved aqueous solubility at least 5-fold, compared to 
ketoprofen alone, while also exhibiting appreciable lipophilicity. In vitro passive diffusion 
studies revealed that ketoprofen in its native form was delivered to a greater extent, compared 
with a dendrimer-conjugated form at the end of 24 h (Q24h (µg/cm
2
): ketoprofen (68.06±3.62) > 
D2 (49.62±2.92) > D4 (19.20±0.89) > D1 (6.45±0.40) > D3 (2.21±0.19). However, sonophoresis 
substantially increased the skin permeation of ketoprofen-dendrimer conjugates in 30 min (Q30min 
(µg/cm²): D4 (122.19±7.14) > D2 (66.74±3.86) > D1 (52.10±3.22) > D3 (41.66±3.22) although 
ketoprofen alone again proved superior (Q30min: 167.99±9.11 µg/cm²). Next, application of 
iontophoresis was trialed and shown to considerably increase permeation of dendrimeric 
ketoprofen in 6 h (Q6h (µg/cm
2
): D2 (711.49±39.14) > D4 (341.23±16.43) > D3 (89.50±4.99) > 
D1 (50.91±2.98), with a Q6h value of 96.60±5.12 µg/cm
2
 for ketoprofen alone). In vivo studies 
indicated that therapeutically relevant concentrations of ketoprofen could be delivered 
transdermally when iontophoresis was paired with D2 (985.49±43.25 ng/ml). Further, 
histopathological analysis showed that the dendrimeric approach was a safe mode as ketoprofen 
alone. The present study successfully demonstrates that peptide dendrimer conjugates of 
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ketoprofen, when combined with non-invasive modalities, such as iontophoresis can enhance 
skin permeation with clinically relevant concentrations achieved transdermally. 
Keywords: Ketoprofen, dendrimeric conjugates, passive diffusion, sonophoresis, iontophoresis, 
skin permeation 
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1. INTRODUCTION 
Historically, the skin was thought to be totally impervious to exogenous chemicals 
(Scheuplein and Blank, 1971). However, once it was implicit that the skin was a semi-permeable 
membrane rather than a totally impervious barrier; there arose new possibilities for the use of 
this route as a portal for systemic drug absorption. In general, the epidermis (more specifically 
the stratum corneum – the top-most skin layer) limits the delivery of drug molecules. Only low 
molecular weight drugs (generally <500 Da) with adequate physicochemical properties can be 
passively transported through skin (Prausnitz et al., 2004). Various approaches have evolved to 
expand the number of drugs delivered through skin using formulation manipulation like 
supersaturated solution, microemulsion, liposomal systems, and chemical enhancement using 
permeation enhancers such as polyalcohols, pyrrolidones, amines, amides, fatty acids, 
sulphoxides, esters, terpenes, alkanes, surfactants and phospholipids (Barry et al., 2004). 
Physical penetration enhancement methods like iontophoresis, sonophoresis, electroporation and 
magnetophoresis have also been studied with promising outcomes achieved (Patel and Trivedi, 
2011). 
In recent years, dendrimers have been identified as permeation enhancers for skin 
delivery of drugs. The development of dendrimers as potential drug vehicles or scaffolds now is 
one of the most active areas of biomedical and pharmaceutical sciences (Cheng and Xu, 2008). 
Dendrimers are hyperbranched macromolecules having a tree-like structure, consisting of a core 
from which alternating layers of monomers extend. They possess several features such as regular 
branching, multivalency, small-size, high density of surface-functional groups, extremely low 
polydispersity, host-guest entrapment properties and precise molecular weight. There are reports 
on the use of dendrimers, specifically poly(amidoamine) (PAMAM) systems, in transdermal 
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drug delivery prepared as PAMAM-drug conjugates (Najlah et al., 2006; Kumar et al., 2010). 
Although PAMAM dendrimers exhibited promise in the delivery of drugs like 5-fluorouracil, 
tamsulosin, indomethacin, ketoprofen, riboflavin and diflunisal, their biodegradation and 
inherent cytotoxicity remains an issue (Duncan & Izzo, 2005; Venuganti et al., 2008).  
Peptide dendrimers have a wedge-like macromolecular structure. They are composed of 
amino acids connected via peptide/ amide bonds which are present within the branching core as 
well as on their outer surface. They have many advantages including lower toxicity, 
biodegradation as well as cost effectiveness to prepare in bulk. Encapsulation and conjugation of 
drugs with peptide dendrimers have been studied for delivery of hydrophobic drugs (Gajbhiye et 
al., 2008), and this study explores the application of peptide dendrimers for drug delivery, and is 
an extension of our earlier work (Mutalik et al., 2009, Mutalik et al., 2011; Mutalik et al., 2013; 
Mutalik et al., 2014; Shetty et al., 2017). In this study, we have synthesized dendrimeric 
conjugates of ketoprofen using different natural amino acids. The release of drug from a 
conjugate occurs via chemical or enzymatic cleavage of a hydrolytically labile bond. 
Ketoprofen was chosen as a model drug in this study given is available in topical form, 
serving as a non-steroidal anti-inflammatory agent (NSAID) with analgesic and antipyretic 
properties. The importance of ketoprofen in the therapeutic field has stimulated the development 
of topical dosage forms to improve its percutaneous absorption (Moretti et al., 2000). 
Pertaining to application of peptide dendrimers in skin/ transdermal delivery of bioactive 
molecules, we have previously studied the passive diffusion and the effect of sonophoresis and 
iontophoresis on the penetration of peptide dendrimers across human skin (Mutalik et al., 2012; 
Mutalik et al., 2013). Additionally, enhancement in deposition and permeation of 5-fluorouracil 
across human epidermis assisted by peptide dendrimers was also investigated (Mutalik et al., 
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2014). There are few reports available on the conjugation of drugs such as paclitaxel and 
methotrexate with PAMAM dendrimers. However these reports revealed the possible risks 
associated with these PAMAM dendrimeric conjugates in therapeutic use (Myc et al., 2008; 
Cline et al., 2013; Satsangi et al., 2014). Having understood this, we have now transitioned to 
assess chemically conjugated ketoprofen-peptide dendrimers for transdermal drug delivery on 
which no reports are available in the literature. In addition, the effect of sonophoresis and 
iontophoresis on the permeation of these dendrimeric conjugates, along with histological 
evaluation was studied.  
2. MATERIALS AND METHODS 
2.1. Materials 
Ketoprofen was kindly gifted by T & T Pharma Care Pvt. Ltd., Mumbai, India. Fmoc-
Gly-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-Arg(Pbf)-OH, O-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluroniumhexafluorophosphate (HBTU) and Rink amide resin were procured from 
Merck Biosciences AG, Darmstadt, Germany. Dichloromethane (DCM), acetonitrile and N,N-
dimethylformamide (DMF) were purchased from RCI Labscan, Samutsakorn, Thailand. 
Trifluoroacetic acid (TFA), N,N-diisopropylethylamine (DIEA), triisopropylsilane (TIPS), N-
methyl pyrrolidine (NMP), HEPES, piperidine, diethyl ether, and acetaminophen were purchased 
from Sigma-Aldrich, St. Louis, Mo., USA. Heptafluorobutyric acid (HFBA) was obtained from 
Fluka Chemie GmbH, Buchs, Switzerland. 
Male Swiss Albino mice (6-8 weeks old; 20-25 g) were used in this study. The animal 
experimental protocol was approved by Institutional Animal Ethical Committee, Kasturba 
Medical College, Manipal University, Manipal (Approval No.: IAEC/KMC/12/2014). 
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2.2. Synthesis, purification and characterization of dendrimeric conjugates of ketoprofen 
In total, four peptide dendrimeric conjugates of ketoprofen, having either 2
+
 or 4
+
 charge 
were synthesized by Fmoc Solid Phase Peptide Synthesis (SPPS) (Mutalik et al., 2011). Details 
of the dendrimeric conjugates are given in Table 1 and the synthesis scheme is given in Figure 1. 
Rink-amide resin was treated with DMF and Fmoc removal achieved with 20% v/v piperidine in 
DMF. Firstly, Fmoc-Gly-OH activated with HBTU and DIEA was coupled to the resin. The 
resin was then washed with DMF, and treated with 20% v/v piperidine in DMF prior to coupling 
of the next amino acid. This successive process was continued until the required dendrimeric 
conjugates of ketoprofen were formed. At each step of amino acid coupling, the coupling 
efficiency was established by the Ninhydrin test. Next amino acid was coupled only after 
achieving at least 99% coupling of the preceding amino acid. Once the desired peptide 
dendrimeric conjugate of ketoprofen was synthesized, terminal Fmoc groups were detached. This 
step was followed by flow washing with MF, then DCM and vacuum-drying of the resin. The 
peptide dendrimer-ketoprofen conjugates were then separated off-resin by stirring the product in 
a mixture of TFA, DCM, water and TIPS (90:5:2.5:2.5) for 3-4 h. The resin mixture was then 
filtered, and TFA eluent removed in vacuo. The subsequent residue was treated with toluene (3 x 
50 mL), mixed vigorously with ice-cold diethyl ether (3 x 20 mL) and lyophilized. 
The dendrimeric conjugates of ketoprofen were purified using a preparative HPLC 
(Waters, Milford, MA, USA) and subjected to mass spectrometry (MS) analysis, differential 
scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and zeta potential 
measurements. In MS analysis, all the synthesized dendrimeric conjugates of ketoprofen (D1, 
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D2, D3 and D4) were analyzed using ESI
+
-MS (2000 QTRAP Nano spray
TM
, MDS Sciex, a 
division of MDS Inc., Ont., Canada) for their molecular ion [M+H]
+
. 
For DSC analysis, the sample (plain ketoprofen and D1, D2, D3 or D4 conjugates) was 
sealed in an aluminium pan and scanned using a Differential scanning calorimeter (DSC-60; 
Shimadzu, Kyoto, Japan) between 25 and 300 °C, under nitrogen flow (30 mL/ min), at a heating 
rate of 5 °C/min. The reference used was an empty aluminium pan. Temperature calibration was 
done using indium as the standard (Devarakonda et al., 2005). 
Infrared spectroscopy was performed using IR Spectrophotometer (FTIR 8300 
Spectrophotometer, Shimadzu, Kyoto, Japan). The samples were mixed with KBr (200-400 mg) 
and compressed into discs by applying a pressure in a hydraulic press. The pellet was placed in 
the light path and the spectrum was recorded in the region of 4000 to 400 cm
-1
. 
Zeta potential was measured using a Zetasizer (Nano ZS, Malvern Instruments, UK). 
Ketoprofen, D1, D2, D3 or D4 were prepared in HEPES buffer pH 7.4 to get a concentration of 1 
mg/ml each. Ten measurements were taken for each sample and the mean was reported. 
2.3. Solubility Studies  
Ketoprofen alone or dendrimeric conjugates (D1, D2, D3 and D4) were added to Ria 
tubes containing 3 mL of water. Excess quantity was added to ensure that the drug was saturated. 
The vials were kept on Rotospin rotary mixer (Tarsons, Kolkata, India) at 30 rpm for 24 h. The 
samples were passed through 0.45 µm membrane filter and diluted appropriately with water. The 
amount of drug dissolved was determined by using HPLC. 
2.4. Partition coefficient (PC) determination 
Saturated solutions of plain ketoprofen, D1, D2, D3 and D4 in Milli-Q water were 
prepared and the initial concentration of drug in the aqueous phase was analyzed by HPLC. The 
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volume of n-octanol used for the determination of partition coefficient was 1 mL and the final n-
octanol/water phase ratio was 1:1. Known volumes of saturated solution of ketoprofen/ 
dendrimeric conjugates were mixed with same volume of n-octanol and the mixture was 
subjected to shaking using Rotospin rotary mixer (Tarsons, Kolkata) for 24 h. The partition 
coefficient was calculated using following equation: 
Partition coefficient = (drug)oil/(drug)aqueous 
2.5. Cleavage of ketoprofen from its dendrimeric conjugate  
Trypsin was used to demonstrate cleavage of ketoprofen from its dendrimeric conjugates. 
All the conjugates were mixed with trypsin (1:3 molar ratios) and kept under stirring for 4 h at 37 
ºC. At the end of four hours, samples were withdrawn and subjected to MS analysis to check for 
the presence of drug peak. 
2.6. In vitro skin permeation studies (passive diffusion) 
The diffusion cells (vertical type) with a diffusion area of 1.13 cm
2
 and receptor 
compartment volume of 3.5 ml were used in the in vitro skin permeation studies. The abdominal 
portion of the male Swiss Albino mice was shaved with an electrical clipper on the previous day 
of the experiment. After sacrificial, the abdominal skin of the mice was excised, subcutaneous fat 
was removed and the skin was washed under running water. Then the skin was fixed in the 
diffusion cell and the stratum corneum faced the donor compartment. Donor solution comprised 
of 15 mM HEPES +75 mM NaCl and its pH adjusted to 7.4 with 1 M NaOH. Receptor solution 
comprised of 20 mM HEPES + 50 mM NaCl and its pH adjusted to 7.4 with 1 M NaOH to 
mimic the in vivo ionic concentration (Mutalik et al., 2013). This pH was selected taking into 
consideration the possibility of irritation or damage to the skin at lower and higher pH values 
(Jalwal et al., 2010). The whole cell system was maintained on a magnetic stirrer and the 
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receptor solution was stirred using a magnetic bead at a speed of 600 rpm. Drug dispersion (5 
mg/mL in HEPES donor solution, pH 7.4) was added to the donor compartment and HEPES 
receptor buffer pH 7.4 was added to the receptor compartment. Similarly saturated solutions of 
D1, D2, D3 and D4 in HEPES donor solution (pH 7.4) were used in donor compartment. 
Samples (0.5 mL) were collected from the receptor compartment at time different time intervals 
between 0 and 24 h and an equal volume of plain receptor solution was replaced each time into 
the receptor compartment. The mixture was filtered through 0.45 µ and the amount of ketoprofen 
permeated was assayed by HPLC. 
2.7. In vitro skin permeation studies with application of ultrasound (sonophoresis) 
These experiments were conducted in a manner similar to the above, with ultrasound 
applied to the donor compartment. Ketoprofen dispersion (5 mg/mL) or its dendrimeric 
conjugates (D1, D2, D3 and D4) in pH 7.4 HEPES solution were added to the donor 
compartment and low frequency ultrasound was applied using a probe sonicator (VibraCell VC 
130, Sonics and Materials, Newton, CT, USA). The tip of the probe was maintained at a distance 
of 3-5 mm from the skin. Ultrasound was applied for 30 min at the amplitude of ~30 to attain a 
power output of 7-8 W/cm
2 
(Mutalik et al., 2011). Sample collection was performed at the end of 
15 and 30 min. On-off cycle of 1 sec was followed, i.e. ultrasound on for 1 sec, then off for 1 
sec, again on for 1 sec, then off for 1 sec. This was followed to prevent drastic increase in 
temperature in during sonication. Replacement of donor solution every 2 min was also done to 
prevent the increase in temperature. For example: collection of 15
th
 minute sample involved 2 
min sonophoresis; 1 min- donor solution replacement; 2 min- sonophoresis; 1 min- donor 
solution replacement; 2 min- sonophoresis; 1 min- donor solution replacement; 2 min 
sonophoresis and 1 min donor solution replacement. Samples of 0.5 mL were collected from the 
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receptor compartment and an equal volume of buffer was replaced. The mixture was filtered 
through 0.45 µ and analyzed by HPLC. 
 
2.8. In vitro skin permeation studies with application of electric current (iontophoresis) 
Horizontal diffusion cells of 2.5 mL capacity were used for all in vitro iontophoretic 
studies. Silver (Ag) rod and silver chloride (AgCl) rod were used as anode and cathode, 
respectively. Silver-Silver chloride (Ag-AgCl) electrodes were used as they do not cause 
electrolysis of water and hence would not lead to pH shifts in the solution (Rootare et al., 1977). 
A constant current (D.C.) of 0.38 mA/cm
2
 was applied in all the experiments. The dispersion of 
ketoprofen or D1, D2, D3 and D4 conjugates in HEPES solution of pH 7.4 were added to donor 
compartment. Samples (0.4 mL) were withdrawn at different intervals between 0 and 6 h from 
the receptor compartment. The mixture was filtered through a 0.45 µm membrane and analyzed 
by HPLC. 
2.9. In vivo skin permeation study of ketoprofen and dendrimeric conjugate (D4) – 
application of ultrasound 
The animals were divided into 2 groups of 6 animals each. One group was treated with 
plain ketoprofen and the other one was treated with D4 conjugate. Male mice (whose abdominal 
fur had been shaved off on the previous day) were anaesthetized by i.p. administration of 
ketamine hydrochloride. After about 10 min into anesthesia, the mice were fixed on their backs 
and the donor compartment of the vertical diffusion cell was glued on the mice abdomen using 
minimal amount of grease on the outer edge of the flange. Adhesive tape was also used to 
prevent leakage of the drug solution from the diffusion cell. The donor compartment was filled 
with ketoprofen or D4 dendrimeric conjugate dispersion (5 mg/mL) in HEPES solution of pH 
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7.4. Ultrasound was applied by immersing the transducer in the donor solution. The location of 
the center of the diffusion cell was chosen so as to prevent application of ultrasound directly to 
bone close to the surface, which might have caused damage to the blood capillaries around the 
bone. The tip of the probe was maintained at a distance of 3-5 mm from the skin. The ultrasound 
application procedure was similar to the in vitro experiments. At the end of 15 min and 30 min, 
blood (about 300 µL) was withdrawn by retro orbital puncture into heparinized tubes. The blood 
samples were immediately centrifuged to separate the plasma and the latter was stored at -20°C. 
The amount of ketoprofen in the samples was estimated by HPLC.  
The abdominal skin was excised and subjected to histopathological studies after H & E 
staining microscopically with respect to different parameters such as degeneration, necrosis, 
congestion, inflammation, cavitation and edema. The histopathological parameters were scored 
using the following scale: 
Histopathological scale: + = slight; ++ = moderate; +++ = severe. 
2.10. In vivo skin permeation study of ketoprofen or dendrimeric conjugate (D2) – 
application of electric current 
 This was carried out in a manner similar to the above procedure. The donor compartment 
was filled with ketoprofen or D2 dendrimeric conjugate dispersion (5 mg/mL) in HEPES 
solution of pH 7.4. One of the electrodes was placed in the donor solution without touching the 
skin. The tip of other electrode was wound with cotton dipped in receptor solution and placed at 
an area close to the breast to complete the electrical circuit. The animals were divided into 2 
groups of 6 animals each. One group was treated with ketoprofen (cathodic iontophoresis) 
whereas the other was treated with D2 (anodic iontophoresis). At the end of 1 and 3 h, blood 
(about 300 µL) was withdrawn by retro orbital puncture into heparinized tubes. The blood 
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samples were immediately centrifuged to separate the plasma and the latter was stored at -20 °C. 
The drug content in the samples was determined by HPLC. The abdominal skin was excised and 
subjected to histopathological studies microscopically after H&E staining as explained above. 
2.11. HPLC analysis of ketoprofen 
Analysis was done by modifying a previously reported RP-HPLC method (Ahmed and 
Fatahalla, 2007; Boppana et al., 2015; Manikkath et al., 2017). Shimadzu (Kyoto, Japan) HPLC 
system consisted of a degasser (DGU 20As Prominence), a system controller (CBM-20A 
Prominence), pumps (LC-10 AD), an auto-injector (SIL-10AXL) and a variable-wavelength 
UV/Vis detector (SPD-10A). The chromatographic data was analyzed using LC solution 1.24 
SP1 software. The HPLC column was a reverse phase C18 column (RP-C18 Genesis; particle 
size 5 µm; 250 × 4.6 mm), maintained at 25 ºC. Acetonitrile and potassium dihydrogen 
phosphate buffer (pH 3, 10 mM) mixture (55:45) was used as the mobile phase at a flow rate of 
0.8 mL/min. The total run time for each sample was 20 min. The detector wavelength was set at 
260 nm and the volume of injection volume was 100 µL. The retention time of ketoprofen was 
found to be 8.06 min and there were no interfering peaks from skin. The bio-analytical method 
was developed in a similar manner (Boppana et al., 2015). Lercanidipine was used as the internal 
standard (IS). The retention time of ketoprofen was found to be 7.6 min and that of the IS was 
10.3 min. 
 
3. RESULTS AND DISCUSSION 
3.1. Dendrimer Synthesis and Purification 
Dendrimeric conjugates of ketoprofen containing varying positive charges were 
synthesized by Fmoc SPPS (Figure 1). The chemical structures of the peptide dendrimeric 
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conjugates of ketoprofen are shown in Figure 2. The yield of all dendrimers after purification 
was >70%. In their characterization using ESI
+
-MS (QTRAP LC/MS/MS system), all 
dendrimers showed the desired molecular ion [M+H]
+
, confirming the formation of respective 
peptide dendrimeric conjugates (Table 1).  
3.2. Chemical and physicochemical Characterization of conjugates 
3.2.1. Mass spectrometry results:  
From the MS spectral analysis it was observed that the dendrimeric conjugates showed 
the desired molecular ion [M+H]
+
, viz., D1, D2, D3 and D4 showed the respective [M+H]
+
 peaks 
of 879.53, 823.52, 987.52 and 931.51, confirming the formation of respective conjugates. The 
[M+H]
+
 peak corresponding to plain ketoprofen was absent in these MS spectra. The results are 
shown in Table 1 and Figure 3.  
3.2.2. FTIR Analysis 
The results of FTIR spectroscopy (Figure 4) were indicative of the formation of CONH 
bond and thereby support of the formation of peptide dendrimeric conjugates of ketoprofen. The 
IR spectrum of ketoprofen, as shown in Figure 4A, exhibited characteristic peaks at 3730 cm
-1 
(OH group), 3026.31 cm
-1
 (aromatic C-H stretch), 2993 cm
-1
 (C-H alkane stretch), 2937.59 cm
-1 
(CH3 group), 2360.87 cm
-1
(carboxylic acid group), 1697 cm
-1 
(COOH containing C=O group), 
1654.36 cm
-1
 (C=O group), 1579.70 cm
-1 
(aromatic -C=C- bend). 
FTIR spectra of D1 (Figure 4B) exhibited merged peaks at 3591.46 cm
-1
 (-NH-; 2º 
amine), 3070.68 cm
-1
 (=C-H stretch), 2939.52 cm
-1
 (C-H alkyl stretch), 1739 cm
-1 
(C=O stretch), 
1678.07 cm
-1
 (C=O group) and 1653 cm
-1
 (C=N group, indicating the presence of amino acids). 
FTIR spectra of D2, as shown in Figure 4C, exhibited peaks at 3059.10 cm
-1
 (=C-H 
stretch), 3670.54 cm
-1
 (O-H stretch), 2941.44 cm
-1
 (C-H alkyl stretch), 1678.07 cm
-1
 (C=O 
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group) and 1653 cm
-1
 (C=N group, indicating the presence of amino acids), 1454.33 cm
-1
 (C-H 
bend alkanes). 
FTIR spectra of D3 exhibited peaks at 3564.45 cm
-1
 (O-H stretch), 2939.52 cm
-1
 (C-H 
alkyl stretch), 1739.79 cm
-1
 (C=O stretch), 1653 cm
-1
 (C=N group, indicating the presence of 
amino acids), 1541.12 cm
-1
 (C-C aromatic stretch), 1454.33 cm
-1
 (C-H bend alkanes), 1315.45 
cm
-1
 (C-O stretch), 1047 cm
-1
 (C-N stretch, aliphatic amine) as shown in Figure 4D. 
FTIR spectra of D4 (Figure 4E) exhibited peaks at 3610.74 cm-1 (O-H stretch), 3277.06 
cm
-1
 (N-H stretch), 3061.03 cm
-1
 (C-H aromatic stretch), 2939.52 cm
-1
 (C-H alkane stretch), 
1678.07 cm
-1
 (C=O stretch), 1516.05 cm
-1
 (C-C aromatic stretch), 1454.33 cm
-1
 (C-H bend 
alkanes), 1286.52 cm
-1
 (C-O stretch), 1201.65 cm
-1
 (C-N stretch). 
3.2.3. Differential Scanning Calorimetry (DSC) Results 
The DSC thermograms are given in Figure 5. The DSC thermogram of pure ketoprofen 
showed a sharp endothermic peak at 99.5 ºC, corresponding to its melting point. In all the 
thermograms of the dendrimeric conjugates of ketoprofen, the peak of ketoprofen was absent. 
Endothermic peaks with low intensity were observed in the thermograms of the dendrimeric 
conjugates; near the melting points of lysine, glycine and arginine (224, 245 and 235 ºC, 
respectively). In a previous report also, the drug peak disappeared when complexed with 
PAMAM dendrimer which was attributed to decreased heats of fusion of the drug in the presence 
of dendrimers (Devarakonda et al., 2005). These results are collectively in favor of formation of 
ketoprofen-dendrimer conjugates.  
3.2.4. Zeta potential Results 
Zeta potential of all the dendrimeric conjugates of ketoprofen exhibited positive charge at 
pH 7.4 (D1=0.91±0.02 mV; D2=6.95±0.12 mV; D3=1.61±0.05 mV; D4=6.17±0.09 mV). 
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Ketoprofen showed a zeta potential of -12.5±0.81 mV. The positive zeta potential values of the 
conjugates are clearly indicative of the conjugation of ketoprofen with peptide dendrimer 
(Mutalik et al., 2012). 
 
3.2.5. Solubility studies 
All the dendrimeric conjugates showed higher solubility in water as compared to 
ketoprofen (58.54±0.21 µg/mL). Among the conjugates, D4 showed the highest solubility, 
(558.31±15.1 µg/mL) followed by D2 (392.50±11.1 µg/mL), D1 (317.98±9.2 µg/mL) and D3 
(267.02±5.6 µg/mL). This confirms the hydrophilic nature of dendrimeric conjugates of 
ketoprofen in comparison with plain drug. These results are in agreement with previous results 
where PAMAM dendrimers exhibited enhanced solubility for ketoprofen. The extent of increase 
in solubility of ketoprofen with peptide dendrimers was noted to be less than that attained with 
PAMAM dendrimers; however, the PAMAM dendrimers were of a higher generation (charge) 
and MW (Yiyun et al., 2008). 
3.2.6. Partition coefficient studies 
Ideal drug candidates for transdermal drug delivery should possess Log P between -1 to 4 
(Panchagnula, 1997). Plain ketoprofen (Log P value: 1.22) and all the synthesized dendrimeric 
conjugates of ketoprofen also showed the Log P values between -1 to 4 indicating sufficient 
lipophilicity as required for skin delivery of the conjugates. The Log P value of ketoprofen 
obtained in this study is in close agreement with previous reports (Schmitt and Guentert, 1990). 
The lipophilicity of the conjugates was ordered as follows, with D2 conjugate having highest 
lipophilicity: 
D2 (-0.24±0.02) > D4 (-0.74±0.05) > D1 (-0.81±0.06) > D3 (-0.99±0.07). 
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From the partition coefficient measurements there is an evidence to indicate that 
conjugation of peptide dendrimers with ketoprofen alters its solubility and partition coefficient, 
suggesting that it may therefore alter the skin partitioning.  
 
3.3. Cleavage of ketoprofen from its dendrimeric conjugate 
It is important that ketoprofen should be released/ cleaved off from its conjugated form 
when it enters the skin. Trypsin, present in the skin, selectively cleaves the molecules with amino 
acids such as lysine and arginine. Koshikawa et al. (1998) demonstrated that trypsin is 
extensively expressed in the cells lining the skin, stomach, small intestine, liver and kidney as 
well as in the leukocytes of the spleen and nerve cells in the brain.  Since all our synthesized 
peptide dendrimeric conjugates contain these amino acids, trypsin was used to observe whether 
ketoprofen would be cleaved/ released within the skin from its conjugated form. As discussed 
previously in Section 3.2.1, MS spectra of dendrimeric conjugates did not show the presence of 
free ketoprofen. It is expected that if the cleavage takes place, then MS analysis should reveal the 
molecular ion of ketoprofen. The results indicated the presence of [M+H]
+ 
peak of ketoprofen 
(255.40) in all MS spectra obtained with D1 to D4 peptide dendrimeric conjugates after treating 
with trypsin. These observations clearly demonstrate the cleavage/ release of ketoprofen from its 
conjugated form within the skin. The typical MS chromatogram of cleavage study with D1 
conjugate is shown in Figure 6. 
3.4. In vitro skin permeation studies 
3.4.1. In vitro passive diffusion studies 
The results of permeation of plain ketoprofen and its dendrimeric conjugates across 
mouse skin are shown in Figure 7. The amount of ketoprofen permeated at the end of 24 h (Q24h) 
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was 68.06±3.62 µg/cm
2
. These results are supported by the data of previous studies where 
ketoprofen permeation was about 75 µg at the end of 24 h across the rat skin (Yiyun et al., 2007). 
It was observed that permeation of ketoprofen from its conjugates was considerably less when 
compared to plain ketoprofen. This could be due to high molecular weight (MW ≈1000) of the 
dendrimeric conjugates. Among the conjugates the permeation rate followed the pattern as 
shown below: 
Q24h (µg/cm
2
): D2 (49.62±2.92) > D4 (19.20±0.89) > D1 (6.45±0.40) > D3 (2.21±0.19).  
These Q24h values are in accordance with partition coefficient results (Section 3.2.6). 
Lipophilicity of the penetrant is an important parameter that determines the extent of skin 
permeation. To a certain extent, higher lipophilicity of the molecules results in higher skin 
permeation. These results also indicate the importance of charge and MW of the conjugates. 
Higher permeation was observed with D2 conjugate (higher charge of 4
+ 
and low MW). 
Similarly less permeation was observed with D3 conjugate (lower charge of 2
+ 
and higher MW). 
However D1 and D4 did not exhibit expected dependency on MW and charge. This suggests that 
a combination of multiple factors such as partition coefficient, architecture, surface charge and 
MW influence permeation. 
3.4.2. In vitro skin permeation studies with application of ultrasound (sonophoresis) 
Once the passive diffusion of ketoprofen and its dendrimeric conjugates was studied, next 
step was to evaluate the effect of ultrasound on the transdermal permeation of ketoprofen in its 
plain- as well as in conjugated form. Sonophoresis is an effective strategy over passive diffusion 
in the transdermal and topical delivery (Herwadkar et al., 2012). The results of sonophoretic 
transdermal permeation of ketoprofen and its dendrimeric conjugates for 30 min are shown in 
Figure 8. 
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Appreciable amount of ketoprofen was permeated in 30 min with the aid of ultrasound. 
The amount of ketoprofen permeated from its plain form as well as from its dendrimeric 
conjugates in 30 min (Q30min) with sonophoresis was more than the amount that permeated in 24 
h with simple passive diffusion study. Highest skin permeation was shown by plain ketoprofen 
(Q30min = 167.99±9.11 µg/cm
2
) upon ultrasound application when compared to conjugates. This 
again could be attributed to the low molecular weight and high partition coefficient value of 
plain ketoprofen. The permeation rate of conjugates followed the pattern as shown below: 
Q30 min (µg/cm
2
): D4 (122.19±7.14) > D2 (66.74±3.86) > D1 (52.10±3.22) > D3 
(41.66±3.22). 
The skin permeation trend observed with ultrasound application did not completely rely 
on MW or lipophilicity of dendrimeric conjugates. 
For example: D4 conjugate ([M+H]
+
=931.51), despite having higher MW than D1 
([M+H]
+
=879.53) and D2 ([M+H]
+
=823.52), exhibited higher permeation upon application of 
ultrasound. Likewise, D2 (Log P= -0.24) with high lipophilicity exhibited lower Q30min value in 
comparison with D4 (Log P= -0.74) which showed highest skin permeation upon ultrasound 
application although its partition coefficient value was less than that of D2. Hence the trend 
observed in the skin permeation of dendrimeric conjugates in sonophoresis did not follow MW 
as well as partition coefficient dependency completely. There may be some other factors that 
play important role in transdermal permeation of these peptide dendrimeric conjugates of 
ketoprofen. 
3.4.3. In vitro skin permeation studies with application of electric current (iontophoresis) 
Iontophoresis improves the delivery of polar molecules as well as high molecular weight 
compounds such as peptides and oligonucleotides (Escobar-Chávez et al., 2012). In a previous 
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study, iontophoresis increased the permeation of ketoprofen through human cadaver skin in 
comparison to passive diffusion (Panus et al., 1997).The results of iontophoresis of ketoprofen 
and its dendrimeric conjugates are shown in Figure 9. The amount of ketoprofen permeated at 
the end of 6 h (Q6h) observed with cathodic iontophoresis of ketoprofen was found to be 
96.60±5.12 µg/cm
2
.The rate of permeation of the drug with the application of iontophoresis with 
different conjugates (anodic iontophoresis) was observed in the following sequence: 
Q6h (µg/cm
2
): D2 (711.49±39.14) > D4 (341.23±16.43) > D3 (89.50±4.99) > D1 
(50.91±2.98).  
D2 conjugate (with low MW and high positive charge) showed highest skin permeation 
rate for ketoprofen with the assistance of electric current. However a similar trend was not 
wholly evident with other dendrimeric conjugates.  
With respect to lipophilicity, D2 and D4 conjugates with comparatively higher partition 
coefficient values (and hence higher lipophilicity), showed greater skin permeation rates in 
iontophoresis. However same dependency on partition coefficient values was not observed for 
other two (D1 and D3) conjugates. D1 conjugate (Log P= -0.81) exhibited lower skin permeation 
than D3 conjugate (Log P= -0.99), despite being more lipophilic comparatively. 
On the other hand, the Q6h values obtained with iontophoresis were in agreement with the 
zeta potential values of the dendrimeric conjugates. The zeta potential values of dendrimeric 
conjugates were in the order of: D2 > D4 > D3 > D1 (Section 3.2.4) and a similar trend was 
observed with iontophoresis mediated skin permeation rate for different conjugates. However 
more detailed studies are required to confirm the mechanism of transport of these dendrimeric 
conjugates. 
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The interesting point to observe in this iontophoresis study is the lower skin permeation 
rate of plain ketoprofen (upon cathodic iontophoresis) in comparison with D2 and D4, although 
ketoprofen possesses comparatively lower molecular weight and higher Log P values. This may 
be attributed to the perm-selectivity of the skin. The isoelectric point for mouse skin was found 
to be slightly below 3.8 (Alvarez et al., 1998). The skin is positively charged at pH below the pI 
and shows anion perm-selectivity. When pH is above pI, the skin is negatively charged and 
hence illustrates cation perm-selectivity. The net positive charge of the conjugates and the pI 
dependent cation perm-selectivity of the skin would be responsible for greater permeation of 
ketoprofen from conjugates upon anodic iontophoresis in comparison with cathodic 
iontophoresis of plain ketoprofen. 
3.4.4. Comparison of permeation strategies 
When different permeation strategies employed in this study viz. passive diffusion, 
sonophoresis and iontophoresis were compared each other for plain ketoprofen, it was observed 
that permeation of drug was highest with sonophoresis (Q30min: 167.99±9.11 µg/cm
2
) followed by 
iontophoresis (Q6h: 96.60±5.12 µg/cm
2
) and least with passive diffusion (Q24h: 68.06±3.62 
µg/cm
2
). 
For the dendrimeric conjugates, iontophoresis was found to be appropriate mode to 
ensure highest permeation of drug. Anodic iontophoresis of D2 conjugate showed highest 
permeation (Q6h: 711.49±39.14 µg/cm
2
), which was over 7-fold greater than that achieved with 
ketoprofen alone. On the other hand, sonophoretic delivery of ketoprofen from its dendrimeric 
conjugates was lower than that observed with sonophoretic delivery of plain drug, and a similar 
trend was also observed with passive diffusion.  
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Hence, the results of the present study suggest that chemical conjugation of ketoprofen to 
peptide dendrimers may not be a suitable approach to enhance the permeation of drug via passive 
diffusion or sonophoresis. The results demonstrate the need of free peptide dendrimer at the site 
to enhance the permeation of bioactive molecules. Our previous report (Mutalik et al., 2014) on 
the enhancement of transdermal permeation of 5-fluorouracil demonstrated that the presence of 
free peptide dendrimer, which acts as transdermal permeation enhancer, significantly increased 
the skin permeation of drug. 
Chemical conjugation of ketoprofen to peptide dendrimer considerably enhanced the skin 
permeation of ketoprofen via iontophoresis. This might be due to the presence of positive charge 
on the dendrimer, which even after conjugation drives the molecule into the skin when an 
electric current is applied. In support of this, our previous studies have shown that iontophoresis 
can be successfully applied to enhance the transdermal permeation of peptide dendrimers 
(Mutalik et al., 2012). Electro-osmosis might also have played a more active role in transdermal 
permeation of higher MW compounds under the influence of an applied current (Guy et al., 
2000; Mutalik et al., 2012). Overall, these results demonstrate that iontophoresis is a more 
favorable approach for permeation of dendrimeric conjugates of ketoprofen across the skin as 
compared to sonophoresis and passive diffusion. 
Highest skin permeation among the dendrimeric conjugates was observed with D2 
conjugate (iontophoretic delivery) and D4 conjugate (sonophoretic delivery) and hence this was 
selected for further permeation studies in vivo. 
3.5. In vivo studies 
3.5.1. In vivo skin permeation studies with the application of sonophoresis 
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In vivo skin permeation of ketoprofen and its dendrimeric conjugate (D4) in the presence 
of sonophoresis was studied in male Swiss Albino mice and the results are shown in Table 2. 
Plasma concentration of ketoprofen was higher with plain ketoprofen as compared to the 
dendrimeric conjugate (D4). These in vivo results are in support of our in vitro sonophoretic skin 
permeation results where plain ketoprofen showed better skin permeation than the conjugates, 
which can be attributed to the considerably lower MW of ketoprofen, compared to D4 conjugate. 
 
 
3.5.2. In vivo skin permeation studies with the application of iontophoresis 
Iontophoresis assisted in vivo skin permeation study of ketoprofen and D2 conjugate was 
studied. The results (Table 3) indicated that anodic iontophoresis of dendrimeric conjugate 
exhibited higher plasma concentration of ketoprofen as compared to cathodic iontophoresis of 
plain ketoprofen. The reasons as explained under Section 3.4.3 (In vitro skin permeation studies 
with application of electric current (iontophoresis)) may also be responsible for this greater in 
vivo skin permeation of ketoprofen from D2 conjugate under the influence of electric current. 
Our previous reports have demonstrated the usefulness of peptide dendrimeric structures in 
augmenting the permeation of 5-fluorouracil across human skin (Mutalik et al., 2009; Mutalik et 
al., 2013; Mutalik et al., 2014). 
The in vivo skin permeation trend observed with sonophoresis and iontophoresis is in 
accordance with the results obtained with in vitro skin permeation of ketoprofen and its 
dendrimeric conjugates. From the results of in vivo permeation studies, it can be established that 
synthesizing ketoprofen-peptide dendrimeric conjugates is beneficial for iontophoresis mediated 
skin delivery of ketoprofen as compared to ultrasound-assisted delivery. 
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3.5.3. Absorption of ketoprofen: Transdermal route vs. oral administration  
Male Swiss albino mice were orally administered with 20 mg/kg of ketoprofen. The 
plasma concentration of ketoprofen observed at the end 1 h after oral administration was 
compared with that observed with that observed with D2 conjugate + iontophoresis. The results 
indicated that the absorption of ketoprofen after oral administration was rapid and higher than the 
transdermal application of ketoprofen and its dendrimeric conjugate in combination with electric 
current. The plasma concentrations of ketoprofen after transdermal iontophoresis application and 
oral administration were 985.49±43.25 ng/ml (with 1 cm
2
 of application area) and 
8215.56±76.56 ng/ml, respectively. The results clearly demonstrate that the concentration of 
ketoprofen that is observed with oral route can easily be achieved with transdermal iontophoresis 
of peptide dendrimeric conjugate (D2) within an appreciable area of application. In this regard, 
peptide dendrimeric conjugates of ketoprofen can be se successfully applied to enhance the 
transdermal permeation of the drug iontophoretically and to deliver the drug at therapeutically 
effective concentration to systemic circulation through the skin in a non-invasive mode. 
3.5.4. Histopathological evaluation of treated and untreated skin 
In the histolopathological evaluations, normal skin did not show any indication of dermal 
toxicity. Mice treated with ketoprofen + sonophoresis as well as D4 + sonophoresis showed 
slight (scale: +) necrosis, inflammation and cavitation. Additionally D4 + sonophoresis showed 
slight (scale: +) degeneration. The skin treated with ketoprofen + iontophoresis exhibited slight 
(scale: +) inflammation and necrosis. Skin treated with D2 + iontophoresis showed slight (scale: 
+) inflammation, degeneration and necrosis. These results showed higher dermal safety and non-
toxic nature of ketoprofen or dendrimeric conjugates in conjunction with iontophoresis/ 
sonophoresis. 
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4. CONCLUSIONS 
Peptide dendrimeric conjugates of ketoprofen were synthesized using different amino 
acids by Fmoc SPPS. Next, MS, DSC, FTIR and zeta potential measurements confirmed the 
formation of dendrimeric conjugates of ketoprofen. All the peptide dendrimeric conjugates of 
ketoprofen showed higher aqueous solubility and appropriate lipophilicity. he conjugates also 
demonstrated cleavage/ release of ketoprofen when treated with trypsin. Ketoprofen-peptide 
dendrimeric conjugates benefit markedly from iontophoresis-mediated skin delivery as compared 
to ultrasound assisted delivery. In vivo results indicated that therapeutic concentrations of 
ketoprofen could be achieved iontophoretically with D2 conjugate within the area of skin 
application. Importantly, no toxicity was seen with either ketoprofen or dendrimeric conjugates 
in conjunction with sonophoresis or iontophoresis. The present study successfully demonstrates 
the application of chemical conjugates of drug and peptide dendrimers in enhancing the skin 
delivery of drugs. 
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Table 1. Details of different peptide dendrimeric conjugates of ketoprofen synthesized 
Type of  dendrimeric 
conjugate 
Dendrimer sequence 
(C-to-N terminus) 
[M+H]
+
 peak and 
MW (calculated) 
D1 (Arginine 4
+
) Gly-Lys(Keto)-Lys-(Arg)2 879.53; 878.52 
D2 (Lysine 4
+
) Gly-Lys(Keto)-Lys-(Lys)2 823.52; 822.51 
D3 (Arginine 2
+
) Gly-Lys-(Arg-Keto)2 987.52; 986.51 
D4 (Lysine 2
+
) Gly-Lys-(Lys-Keto)2 931.51; 930.50 
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Table 2. In vivo permeation of ketoprofen and its dendrimeric conjugate in the presence of 
sonophoresis 
 
Treatment 
Plasma concentration of ketoprofen  
(ng/ml)* 
15 min 30 min 
Ketoprofen + Sonophoresis 231.42 ± 9.88* 384.91 ± 16.22* 
D4 + Sonophoresis 111.56 ± 6.48 134.59 ± 9.12 
 
 
All the values are expressed as Mean±SD, n=6; * significantly different (p<0.05) compared to 
D4+sonophoresis at the respective time intervals. 
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Table 3. In vivo skin permeation of ketoprofen and its dendrimeric conjugate in the 
presence of iontophoresis 
Treatment 
Plasma concentration of ketoprofen  
(ng/ml)* 
1 h 3 h 
Ketoprofen + Iontophoresis 22.83 ± 1.10 142.11± 6.55 
D2 + Iontophoresis 
249.25 ± 12.12* 985.49 ± 43.25* 
 
All the values are expressed as Mean±SD, n=6; * significantly different (p<0.05) compared to 
D4+sonophoresis at the respective time intervals. 
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Figure 1. Synthetic scheme towards peptide dendrimeric conjugates of ketoprofen 
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Figure 2. Molecular structures of peptide dendrimeric conjugates of ketoprofen  
D1=Gly-Lys(Keto)-Lys-(Arg)2; D2=Gly-Lys(Keto)-Lys(Lys)2; D3=Gly-Lys-(Arg-Keto)2; 
D4=Gly-Lys-(Lys-Keto)2   
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Figure 3. MS Spectra of different ketoprofen-dendrimeric conjugates 
A) D1 (Gly-Lys(Keto)-Lys-(Arg)2), B) D2 (Gly-Lys(Keto)-Lys(Lys)2), C) D3(Gly-Lys-(Arg-
Keto)2) and D) D4 (Gly-Lys-(Lys-Keto)2) 
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Figure 4. IR spectra of ketoprofen and its dendrimeric conjugates  
A) Ketoprofen, B) D1 (Gly-Lys(Keto)-Lys-(Arg)2), C) D2 (Gly-Lys(Keto)-Lys(Lys)2), D) 
D3(Gly-Lys-(Arg-Keto)2) and E) D4 (Gly-Lys-(Lys-Keto)2) 
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Figure 5. DSC thermograms of pure drug (ketoprofen) ketoprofen and its dendrimeric 
conjugates (D1, D2, D3 and D4) 
 
A) Ketoprofen, B) D1 (Gly-Lys(Keto)-Lys-(Arg)2), C) D2 (Gly-Lys(Keto)-Lys(Lys)2), D) 
D3(Gly-Lys-(Arg-Keto)2) and E) D4 (Gly-Lys-(Lys-Keto)2) 
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Figure 6. MS image of D1 peptide dendrimeric conjugate indicating molecular ion peak of 
ketoprofen after treating with trypsin 
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Figure 7. In vitro skin permeation profile of ketoprofen and its dendrimeric conjugates in 
passive diffusion study 
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Figure 8. Skin permeation profiles of ketoprofen and its dendrimeric conjugates across the 
skin with application of ultrasound 
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Figure 9. Iontophoretic skin permeation of ketoprofen and its peptide dendrimeric 
conjugates 
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